Company intelligence / Profile preview

Spectros

Portola Valley, California, USAspectros.com ↗

Ownership: Private
Development stage: Other

Overview

The T‑Stat VLS Tissue Oximeter is FDA-approved and CE-marked for real-time non-invasive monitoring of tissue ischemia. It uses advanced visible light spectroscopy to provide superior accuracy over competing products. Molecular diagnostic tools for breast and prostate cancers are in phase I/II clinical trials with National Cancer Institute support.

Therapeutic areas: OncologyCardiovascular
Modalities: Device (Tissue oximeter)Diagnostic device
Industry: Physiological Monitoring

Partnerships

Endovations AustraliaFysicon Medical Technology NetherlandsA.M.I. Italia s.r.l.Royal Philips Electronics N.V.LI-CORCaliper Life SciencesFirstScanMerck Research LabsRita Medical SystemsBoston Scientific Corporation

Beyond the preview

Go deeper on Spectros.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spectros.

Explore the full profile